Synthesis of Fluoridated Polymer for Self-assembly Nanovaccines with Antigen and Oligodeoxynucleotides for Cancer Immunotherapy
DOI:
https://doi.org/10.47611/jsrhs.v13i3.7494Keywords:
Cancer immunotherapy, Cancer vaccines, Antigen delivery, Fluorinated PEI, DC maturationAbstract
Cancer immunotherapy represents a type of cancer treatment that represses the disease by triggering immune responses. Cancer vaccines play a crucial role in this approach by delivering tumor-specific antigens into antigen-presenting cells which causes an antigen-specific immune response to eliminate cancer cells by effective delivery of antigens into antigen-presenting cells. Effective antigen presentation is critical in eliciting antigen-specific immune responses. Polymers such as dendrimers and polyethyleneimines (PEIs) have been reported for their potential application in delivering antigens and have functioned as vaccine vehicles. However, the cytotoxicity of PEI limits its application as a safe antigen-delivering vector. The fluorination effect can be utilized to reduce cytotoxicity and enhance the efficiency of antigen delivery by forming fluorinated PEI (F-PEI), which can be produced by fluorinating PEI with fluoroalkanes. Due to the low lipophobicity of modified fluoroalkyl chains on polymers, F-PEIs-based nanovaccine for delivering the model antigen ovalbumin (OVA) along with a vaccine adjuvant can induce antigen-specific immune responses targeting cancer. The F-PEI is capable of loading OVA and CpG oligonucleotides (CpG ODN) through electrostatic attraction. The resulting nanovaccine — F-PEI/OVA/CpG — exerts negligible effects on cell viability and effectively enters antigen-presenting cells. According to the observation, F-PEI/OVA/CpG activates bone marrow dendritic cells (BMDCs)’ maturation by upregulating the expression of CD80 protein and CD86 protein, which serve as mature markers for BMDCs. Future research related to F-PEI/OVA/CpG could be extended to different antigens (e.g., neoantigens) and potential clinical applications.
Downloads
References or Bibliography
Zhang, Y. Y., Zhang, Z. M. (2020). The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular & Molecular Immunology, 17 (8), 807-821. https://doi.org/10.1038/s41423-020-0488-6
Wiemann, B.; Starnes, C. O. (1994). Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacology & Therapeutics, 64 (3), 529-564. https://doi.org/10.1016/0163-7258(94)90023-x
Rosenberg, S. A. (2011). Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nature Reviews Clinical Oncology, 8 (10), 577-585. https://doi.org/10.1038/nrclinonc.2011.116
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O'Byrne, K., Kulasinghe, A. (2022). Immune checkpoint inhibitors in cancer therapy. Current Oncology, 29 (5), 3044-3060. https://doi.org/10.3390/curroncol29050247
Vermaelen, K. (2019). Vaccine strategies to improve anti-cancer cellular immune responses. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.00008. eCollection 2019
Ribas, A., Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359 (6382), 1350-1355. https://doi.org/10.1126/science.aar4060
Lehtinen, M., Dillner, J. (2013). Clinical trials of human papillomavirus vaccines and beyond. Nature Reviews Clinical Oncology, 10 (7), 400-410. https://doi.org/10.1038/nrclinonc.2013.84
Shrestha, H., Bala, R., Arora, S. (2014). Lipid-based drug delivery systems. Journal of pharmaceutics, 2014, 801820. https://doi.org/10.1155/2014/801820
Bode, C., Zhao, G., Steinhagen, F., Kinjo, T., Klinman, D. M. (2011). CpG DNA as a vaccine adjuvant. Expert Review of Vaccines, 10 (4), 499-511. https://doi.org/10.1586/erv.10.174
Krieg, A. M. (2006). Therapeutic potential of Toll-like receptor 9 activation. Nature Reviews Drug Discovery, 5 (6), 471-484. https://doi.org/10.1038/nrd2059
Vivero-Escoto, J. L., Slowing, I. I., Trewyn, B. G., Lin, V. S. Y. (2010). Mesoporous Silica Nanoparticles for Intracellular Controlled Drug Delivery. Small, 6 (18), 1952-1967. https://doi.org/10.1126/science.aar4060
Neubi, G. M. N., Opoku-Damoah, Y., Gu, X. C., Han, Y., Zhou, J. P., Ding, Y. (2018). Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy. Biomaterials Science, 6(5), 958-973. https://doi.org/10.1039/C8BM00175H
Liechty, W. B., Kryscio, D. R., Slaughter, B. V., Peppas, N. A. (2010). Polymers for Drug Delivery Systems. Annual Review of Chemical and Biomolecular Engineering, 1, 149-173. https://doi.org/10.1146/annurev-chembioeng-073009-100847
Zhang, Z. J., Shen, W. W., Ling, J., Yan, Y., Hu, J. J., Cheng, Y. Y. (2018). The fluorination effect of fluoroamphiphiles in cytosolic protein delivery. Nature Communications, 9(1) 1377. https://doi.org/10.1038/s41467-018-03779-8
Cametti, M., Crousse, B., Metrangolo, P., Milani, R., Resnati, G. (2012). The fluorous effect in biomolecular applications. Chemical Society Reviews, 41 (1), 31-42. https://doi.org/10.1039/c1cs15084g
Published
How to Cite
Issue
Section
Copyright (c) 2024 ISABELLA XINGYI LI
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
